Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sosei, Allergan Suspend Joint Clinical Development of AD Therapy due to Unexpected Toxicology Findings
September 20, 2018
- Otsuka Pharmaceutical Factory Accuses AY Pharmaceuticals, Yoshindo for Patent Infringement on Transfusion Product
September 20, 2018
- Ono, US Bioventure Fate Therapeutics Hook Up for CAR-T Therapies
September 19, 2018
- Nichi-Iko to Copromote 5 Elmed Eisai Products from October
September 18, 2018
- Astellas Joins Hands with Gene Therapy Biotech for ALS Treatment Program
September 18, 2018
- Takeda Gets China OK for Shire Takeover
September 18, 2018
- Sekisui Chemical Hooks Up with Regenerative Medicine Upstart
September 14, 2018
- Shionogi Grabs Rights to Rohto’s Cell-Based Hepatic Cirrhosis Therapy
September 14, 2018
- Poxel Forms Japan Outpost, Hitches Janssen’s Kaneko as Country Chief
September 14, 2018
- I/O in Lung Cancer - 5: Roche Looks Beyond Tecentriq, Laying Foundation for Next-Gen Immunotherapies
September 13, 2018
- Ex-AZ Exec Nogami Tapped to Lead Takeda Consumer Healthcare
September 13, 2018
- Kowa Continues Heavy GP Pitch for Parmodia in July: Anterio
September 13, 2018
- Nippon Shinyaku Eyes Conditional Early OK for Sakigake DMD Drug, Daiichi Sankyo Redoing PI/II for Its Antisense
September 12, 2018
- Quizartinib Earns Japan Orphan Status for AML: Daiichi Sankyo
September 12, 2018
- Avastin Best-Selling Drug in Japan in August: Encise Snapshot
September 12, 2018
- Risankizumab Hits Primary Endpoint in Japan PII/III Study with Psoriasis Vulgaris Patients: AbbVie
September 11, 2018
- Power Back On at Drug Makers’ Hokkaido Plants
September 11, 2018
- Tremfya Meets Primary Endpoint in Japan PIII Study for Palmoplantar Pustulosis: Janssen
September 11, 2018
- Ethical Drug Sales Up 3.6% in July: Crecon
September 11, 2018
- Shionogi Loses HIV Patent Battle against MSD
September 10, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…